Another example, is the use of anamorelin a ghrelin receptor agonist which maintains lean body mass and has been tested previously for the treatment of cachexia-sarcopenia syndrome in NSCLC (118). This evidence concerns the gene GHSR and non-small cell lung carcinoma.